Interference on metabolism induced by XXXX and @entity9804 in type II hypertensive @entity6 .

@entity1 @entity1369 @entity101 @entity6 @entity2690 @entity1735 @entity9804 @entity551 @entity17132
There is a very high prevalence of @entity101 in @entity6 subjects, which makes it necessary to use an antihypertensive drug with the least possible metabolic interference. For example, in the early phase of @entity101 , diuretics usually worsen the metabolic equilibrium. According to recent reports, a new diuretic, @entity17132 (MZ), which acts on the loop of Henle, seems to present a minor effect on @entity1735 metabolic balance. In order to determine whether this assumption was correct or not, we carried out a clinical trial on 26 type II (non- @entity2690 -dependent) @entity6 , in fairly good metabolic control and with moderate @entity101 (orthostatic diastolic pressure from 100 to 115 mmHg), comparing the effect of MZ with those of @entity9804 (CL). According to a randomized, single-blind cross-over design, the @entity1 were treated with MZ (20 mg/day) or CL (50 mg/day) for the duration of 4 weeks. After the treatment period with the first drug, there was a 2 week wash-out period on placebo (PL) before the second drug was given. During the study, a set of metabolic and non-metabolic parameters was monitored, as were the clinostatic and orthostatic blood pressure values. The results show that the antihypertensive effect of the two drugs was the same (both caused a more than 10% @entity551 ). No significant changes in plasma electrolyte levels occurred. There was a significant (p less than 0.05) increase in urinary @entity1369 excretion after CL (20.7 +/- 11 micrograms/24 hours vs. 13.3 +/- 8.5 after PL, and 14.5 +/- 7.2 after MZ) (mean values +/- standard deviations).(ABSTRACT TRUNCATED AT 250 WORDS)
